Yuexin Health 002162: Investment in artificial reproduction projects mainly include Yichun Maternal and Child Health Hospital in Jiangxi Province and the United States of America Daystar artificial reproduction center, are operating normally. Jindawei 002626: has developed into a rising star in the health care and sports nutrition manufacturing industry.
Sunflower Pharmaceuticals 002737: the company is the production of proprietary Chinese medicines, mainly chemical drugs, biopharmaceuticals, health care products as a supplement, set of pharmaceutical research and development, manufacturing and marketing as one of the large-scale brands of pharmaceutical enterprise groups, the company varieties of rich resources, the product echelon is well-built, and focus on the core varieties, to create the gold single product group. At present, there is no plan to launch new products such as Colla Corii Asini drinks.
Lizhu Group 000513: potential leading respiratory inhalation preparations, the main products include ginseng astragali Fuzheng injection, Lizhu Deluxe (potassium citrate) series of products, antiviral particles HIV antibody diagnostic reagents. The company's business in western pharmaceuticals, APIs, health care products and other stable growth.
Sihuan Bio 000518: The company is a listed pharmaceutical company integrating R&D, production and sales.
Fosun Pharmaceuticals (600196): the company is mainly engaged in the health care industry stocks.
Angie's yeast: the company realized total revenue of $8.933 billion in 2020, up 16.73% year-on-year. The company's management said that the 2021 continuation of the revenue of 10 billion yuan target remains unchanged. It is expected that in 2021 the domestic yeast revenue is expected to maintain a high single-low double growth rate range, yeast extracts, health care products and other growth rate will be around 20%, the overseas market revenue is expected to have a growth rate of 15%-20%.
Pientzehuang: The company realized total revenue of 6.511 billion in 2020, with a year-on-year growth of 13.78%. Pientzehuang is a national certified first-grade protected traditional Chinese medicine, has the right to use the scarce raw material musk, is the leading enterprise of traditional Chinese medicine in liver disease category in China, and its brand value jumps to the first place in the healthcare Hurun list. The company has a strong brand, control of raw materials, expand the channel three core competitiveness, performance continues to grow steadily.
One Network One Creation: 2020 annual report shows that the company's operating income of 1.299 billion yuan, an increase of -10.49% year-on-year, a compound growth of 13.24% over the past three years. The company will hit the explosive product ability to realize, incubating food, health care products private label, to create a second growth curve. It is expected that valuation can be digested by the high growth performance. q3 is expected to continue the company's high growth, is a scarce standard in the cosmetics off-season to maintain high growth.